Cleveland State University

EngagedScholarship@CSU
Biological, Geological, and Environmental
Faculty Publications

Biological, Geological, and Environmental
Sciences Department

9-25-2013

Hedgehog Signaling Regulates Telomerase Reverse Transcriptase
in Human Cancer Cells
Tapati Mazumdar
Cleveland Clinic Foundation

Ranjodh Sandhu
Cleveland State University

Maha Qadan
Cleveland Clinic Foundation

Jennifer DeVecchio
Cleveland Clinic Foundation

Victoria Magloire
Cleveland Clinic Foundation

See next
page
additional
authors
Follow
this
andfor
additional
works
at: https://engagedscholarship.csuohio.edu/scibges_facpub
Part of the Biology Commons

How does access to this work benefit you? Let us know!
Recommended Citation
Mazumdar, Tapati; Sandhu, Ranjodh; Qadan, Maha; DeVecchio, Jennifer; Magloire, Victoria; Agyeman,
Akwasi; Li, Bibo Ph.D.; and Houghton, Janet A., "Hedgehog Signaling Regulates Telomerase Reverse
Transcriptase in Human Cancer Cells" (2013). Biological, Geological, and Environmental Faculty
Publications. 232.
https://engagedscholarship.csuohio.edu/scibges_facpub/232

This Article is brought to you for free and open access by the Biological, Geological, and Environmental Sciences
Department at EngagedScholarship@CSU. It has been accepted for inclusion in Biological, Geological, and
Environmental Faculty Publications by an authorized administrator of EngagedScholarship@CSU. For more
information, please contact library.es@csuohio.edu.

Authors
Tapati Mazumdar, Ranjodh Sandhu, Maha Qadan, Jennifer DeVecchio, Victoria Magloire, Akwasi
Agyeman, Bibo Li Ph.D., and Janet A. Houghton

This article is available at EngagedScholarship@CSU: https://engagedscholarship.csuohio.edu/scibges_facpub/232

Hedgehog Signaling Regulates Telomerase Reverse
Transcriptase in Human Cancer Cells
Tapati Mazumdar1*, Ranjodh Sandhu2, Maha Qadan1, Jennifer DeVecchio1, Victoria Magloire1,
Akwasi Agyeman1, Bibo Li2, Janet A. Houghton1
1 Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America, 2 Department of Biological, Geological and
Environmental Sciences, Center for Gene Regulation in Health and Disease, Cleveland State University, Cleveland, Ohio, United States of America

Abstract
The Hedgehog (HH) signaling pathway is critical for normal embryonic development, tissue patterning and cell
differentiation. Aberrant HH signaling is involved in multiple human cancers. HH signaling involves a multi-protein cascade
activating the GLI proteins that transcriptionally regulate HH target genes. We have previously reported that HH signaling is
essential for human colon cancer cell survival and inhibition of this signal induces DNA damage and extensive cell death.
Here we report that the HH/GLI axis regulates human telomerase reverse transcriptase (hTERT), which determines the
replication potential of cancer cells. Suppression of GLI1/GLI2 functions by a C-terminus truncated GLI3 repressor mutant
(GLI3R), or by GANT61, a pharmacological inhibitor of GLI1/GLI2, reduced hTERT protein expression in human colon cancer,
prostate cancer and Glioblastoma multiforme (GBM) cell lines. Expression of an N-terminus deleted constitutively active
mutant of GLI2 (GLI2DN) increased hTERT mRNA and protein expression and hTERT promoter driven luciferase activity in
human colon cancer cells while GANT61 inhibited hTERT mRNA expression and hTERT promoter driven luciferase activity.
Chromatin immunoprecipitation with GLI1 or GLI2 antibodies precipitated fragments of the hTERT promoter in human
colon cancer cells, which was reduced upon exposure to GANT61. In contrast, expression of GLI1 or GLI2DN in nonmalignant 293T cells failed to alter the levels of hTERT mRNA and protein, or hTERT promoter driven luciferase activity.
Further, expression of GLI2DN increased the telomerase enzyme activity, which was reduced by GANT61 administration in
human colon cancer, prostate cancer, and GBM cells. These results identify hTERT as a direct target of the HH signaling
pathway, and reveal a previously unknown role of the HH/GLI axis in regulating the replication potential of cancer cells.
These findings are of significance in understanding the important regulatory mechanisms that determine the functions of
HH/GLI signaling in cancer cells.
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development, HH signaling activity is essential, being regulated
spatially and temporally resulting in normal tissue patterning and
differentiation. Coordinated HH signaling is also involved in
cellular proliferation and survival, maintenance of stemness and
determination of cell fate [6]. Aberrantly activated HH signaling is
involved in multiple human cancers and it regulates cancer cell
proliferation, survival, cancer stem cell functions, epithelial to
mesenchymal transition and metastasis [6]. We have reported that
HH signaling is critical for the survival of human colon cancer
cells, while blocking these signals induces rapid DNA damage,
culminating in extensive cytotoxicity [7,8,9,10]. Unlimited replication potential of cancer cells is closely associated with cancer cell
survival, however, the role of HH signaling in the replication
potential of cancer cells is not known.
Replication potential of human somatic cells is limited by
special heterochromatic structures known as telomeres at the ends
of linear chromosomes [11]. Mammalian telomeres are comprised
of tandem repeats of TTAGGG sequences that are subjected to
shortening with every DNA replication cycle [12]. Conventional
DNA polymerases are not capable of fully replicating the ends of

Introduction
Classical HH signaling initiates when the soluble HH ligands,
Sonic (SHH), Desert (DHH) or Indian (IHH) HH bind their
transmembrane receptor Patched (Ptch), thereby releasing the
transmembrane protein, Smoothened (Smo) from Ptch-mediated
inhibition. Smo subsequently activates the GLI family of
transcription factors that regulate HH target genes. The GLI
family of transcription factors includes GLI1, GLI2 and GLI3. By
virtue of a C-terminal activator and N-terminal repressor domains,
GLI2 and GLI3 have context-dependent activator or repressor
activity. GLI1 lacks the repressor domain and functions predominantly as an activator [1,2]. GLI2 has a C-terminal activator and
N-terminal repressor domains [3]. GLI2 is reported to be the
initial mediator of HH signaling events, which then induces the
expression GLI1, which further increases HH target gene
expression [4]. When the HH signaling pathway is active, the
latent cytoplasmic GLI proteins translocate to the nucleus where
they bind the GACCACCCA-like elements on the promoters of
the HH-target genes [5,6]. HH signaling regulates cellular events
by modulating specific target genes. During normal embryonic
PLOS ONE | www.plosone.org

1

September 2013 | Volume 8 | Issue 9 | e75253

HH Regulates Human Telomerase in Cancer Cells

linear DNA molecules; hence, telomeric DNA is expected to
shorten with every DNA replication cycle. Critically shortened
telomeres fail to protect chromosomal ends resulting in irreversible
growth arrest and limited cellular lifespan. Hence, telomere
homeostasis is critical for cell proliferation and survival. Telomerase, a ribonucleoprotein comprised of a RNA component (TR)
and a reverse transcriptase catalytic subunit (TERT), replenishes
the telomere repeats and hence regulates cellular replicative
potential [13]. In most adult cells, TR is constitutively present but
TERT expression is repressed, resulting in limited proliferation
potential and cellular life span [14,15]. In actively proliferating
cells such as stem cells and cancer cells, TERT expression is
upregulated resulting in unlimited replicative potential and
immortality of these cells [16]. Human TERT (hTERT)
expression and activity has been evidenced in .75% of human
colorectal cancer cells, but only 3–15% of normal mucosa and
surrounding non-cancerous cells [17]. In concert with its
importance in cancer cell survival, hTERT is stringently regulated
with multiple activators and repressors, of which several have been
identified.
Here we demonstrate for the first time that HH signaling
trancriptionally upregulates hTERT. Suppression of GLI1/GLI2
reduced hTERT protein levels in human colon, prostate and brain
cancer cells. Overexpression of GLI2DN increased the levels of
hTERT mRNA, protein and hTERT promoter-driven luciferase
(luc) activity in colon cancer cells. Blocking GLI1/2 activity
reduced hTERT mRNA expression and the direct interaction
between GLI1/GLI2 proteins and the hTERT promoter in
human colon cancer cells. In contrast, GLI1/GLI2DN expression
in non-cancerous 293T cells did not alter the levels of hTERT
mRNA, protein or hTERT promoter-luc activity. Abrogating HH
signaling in cancer cells decreased the telomerase activity, which
was increased by GLI2DN expression. These results demonstrate
hTERT to be a transcriptional target of the HH signaling pathway
and identify a previously unknown role of the HH/GLI axis in
regulating the replication potential of cancer cells. These findings
reveal a new function of HH signaling in increasing the replicative
ability of cancer cells. Of interest, HH signaling regulates hTERT
in a context-dependent manner in human cancer cells, in contrast
to non-malignant cells, which may have implications in cancer
therapeutics.

purchased from Calbiochem. Dr. Graham W. Neill (Queen Mary
University of London, UK) kindly provided the GLI1 and
GLI2DN plasmids in pBabe-Puro (pBP) mammalian expression
vector. Full-length hTERT-pBP plasmid was a gift of Dr. Robert
Weinberg (Addgene plasmid #1771).

Western Blot Analysis
Total cellular lysates were prepared using RIPA lysis buffer (Cell
Signaling Technology). Protein (60 mg) was resolved on 10% or
5% SDS-PAGE gels. Separated proteins were transferred to
polyvinylidene difluoride membranes and subsequently blocked in
blocking buffer [5% nonfat dry milk in 1X Tris Buffer Saline with
0.1% Tween 20 (TBS-T)] for 1 hour. Membranes were washed in
1X TBS-T, incubated with primary antibody overnight at 4uC,
washed and incubated with secondary antibody for 1 hour, and
finally developed using Super Signal Pico substrate from Pierce
Biotechnology.

RNA Isolation and mRNA Analysis
Total RNA was isolated using the Qiagen RNeasy mini kit
according to the manufacturer’s protocol. Total RNA was
converted to cDNA using random primers (iScript Select cDNA
synthesis kit; BIO-RAD), and used for real-time mRNA expression
analysis using 40 cycles of Applied Biosystems 7500 Real-Time
PCR instrumentation and software. Primers were designed using
NCBI/Primer-BLAST and used to generate the PCR products.
The GLI1, GLI2 and GAPDH primers were previously described
[9].
hTERT
forward
primer:
59CCTGGGTGGCACGGCTTTTGTTC-39.
hTERT
reverse
primer:
59-CAGCCTTGAAGCCGCGGTTGA-39.

GLI3R and Transient Transfections
The myc-tagged C-terminus deleted construct GLI3R (gift of
Dr. Ariel Ruiz i Altaba, University of Geneva Medical School,
Geneva, Switzerland) has been previously described (3). HT29
cells were transiently transfected using Lipofectamine 2000.
(Invitrogen) with GLI3R or the empty vector pCS2-MT (gifted
by Dr. David Turner, at The Molecular & Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, MI). Cells were
used for experiments 24 hr, 48 hr, or 72 hours posttransfection.

Materials and Methods
Cell Culture and Reagents

Chromatin Immunoprecipitation (ChIP) Analysis

HT29, SW480, HCT116 and 293T cells were obtained from
American Type Culture Collection. C4-2, DU145, and PC3 cells
were kind gifts of Dr. Alexandru Almasan (Cleveland Clinic, OH).
U87 cells were a kind gift of Dr. Candece Gladson (Cleveland
Clinic, OH). The cells were routinely verified by microscopic
analysis of cell morphology, growth characteristics, and response
to cytotoxic agents [Annexin V/propidium iodide (PI) staining].
cDNA microarray gene profiles were also characteristic and cells
were verified biannually to be mycoplasma-free. HT29, HCT116,
SW480, C4-2, DU145 and PC3 cells were maintained in 10%
FBS-supplemented RPMI medium while U87 and 293T cells were
maintained in 10% FBS-supplemented DMEM. The cells were
trypsinized and counted using a Z2 Coulter particle count and size
analyzer (Beckman Coulter). For Western analysis, antibody
against HSP90a/b was purchased from Santa Cruz Biotechnology; anti-GLI1 and anti-hTERT antibodies were from Novus
Biologicals, and anti-GLI2 antibody was from Cell Signaling
Technology. Anti-c-myc antibody (9E10) was obtained from the
Hybridoma Core, Lerner Research Institute. GANT61 was

The cells treated with GANT61 (20 mM) for 24 hr were crosslinked in 1% formaldehyde/PBS, 10 min, 37uC, which was
terminated in glycine, 5 min. Cells were washed in PBS and
nuclear extracts prepared. Nuclei were sonicated to generate
chromatin fragments (< 500 to 800 bp). The chromatin was
precleared with a mixture of proteinA-sepharose and proteinGsepharose that was blocked with bovine serum albumin (1 mg/ml)
and Salmon sperm DNA (1 mg/ml). 10% of the precleared
chromatin was used as input control. Equal quantities of the
precleared chromatin fragments were immunoprecipitated with
antibodies specific for GLI1 (Novus Biologicals, CO), GLI2 (Cell
Signaling Technology (MA), IgG (Abcam, MA; negative control),
or histone H3 (Abcam, MA; positive control). Methods were
performed as described previously (3, 4). The immunoprecipitated
products were washed extensively and eluted. 30 ml of the eluted
products were treated with RNase A and Proteinase K followed by
reverse cross-linking and DNA isolation. Gene specific primers
quantified the amounts of hTERT and BCL-2 promoter DNA in
the immunoprecipitated fractions. PCR products were resolved on
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a 1% agarose gel, stained with ethidium bromide, and visualized
under UV light.
The primers used for ChIP analysis are as follows:
hTERT
promoter
forward:
59-TGATGGGGACCGTTCCTTCCATC-39.
hTERT
promoter
reverse:
59-ACACGGCCCACCCAGGGTTTA-39.
BCL2-promoter forward: 59-CCGGACGCGC CCTCCC-39.
BCL-2 promoter reverse: 59-GGTGCCTGTCCTCTTACTTCATTCTC-39.

inhibitors and measured telomerase expression. Human colon
cancer cells HT29 and SW480, exposed to GANT61 (20 mM), a
small molecule inhibitor of GLI1 and GLI2 [9], for 72 hr
demonstrated reduced steady state levels of GLI1, GLI2 and
hTERT proteins (Fig. 1A). Similarly, blocking HH/GLI signaling
in the prostate cancer cells C4-2, DU145 and PC3 also
demonstrated decreased GLI1, GLI2 and hTERT protein
expression (Fig. 1A). Administration of GANT61 (20 mM) to the
GBM cell line U87 over a period of 72 hr resulted in reduced
GLI1, GLI2 and hTERT protein expressions (Fig. 1B). We further
validated the effects of HH signaling pathway on hTERT
expression by genetically modifying the HH/GLI signaling
pathway. We employed a C-terminus deleted mutant of GLI3
(GLI3R, myc-tagged GLI3C’DCla1 [3]), which represses GLI1
and GLI2 activity [8]. Following transient transfection of GLI3R
into HT29 (densitometric quantification in Fig. 2A) and HCT116
(Fig. 2B) colon cancer cell lines, GLI1, GLI2 and hTERT protein
levels were decreased over a period of 48 hr – 72 hr. Conversely,
stable expression of either GLI1 or GLI2DN, an N-terminus
deleted mutant of GLI2, with constitutive activator function in
HT29 cells for 10 passages demonstrated increased hTERT
protein expression (Fig. 2C).

Luciferase Assay
The full-length hTERT promoter (23337/+438), and upstream
deletion mutants (21226/+438 and 2233/+438) -driven luciferase reporter constructs were kindly provided by Dr. Ralf
Janknecht, University of Oklahoma Health Sciences Center, OK
[18]. HT29 or 293T cells were transiently transfected using
Lipofectamine 2000 (Invitrogen) with 4 mg of the luciferase
reporter and 0.4 mg pRLTK (renilla luciferase driven by TK
promoter). 24 hr after transfection, cells were analyzed using the
dual luciferase kit (Promega Corporation) according to the
manufacturer’s protocol. Luciferase activity was detected using
Victor2 multilabel counter, and normalized to renilla luciferase
activity as a control for transfection efficiency.

GLI Transcription Factors Interact with the hTERT
Promoter in Human Cancer Cells

Telomerase Repeat Amplification Protocol (TRAP) Assay

Next, we investigated the mechanism by which HH signals
regulate the expression of hTERT in human cancer cells.
Transcriptional regulation of hTERT expression is a common
mechanism of hTERT upregulation in cancer cells [19]. Since the
GLI proteins are transcription factors, we hypothesized that GLI1
and GLI2 transcriptionally regulate hTERT expression in cancer
cells. hTERT mRNA expression was elevated in both GLI1- and
GLI2-overexpressing HT29 cells (Fig. 3A). When HT29 cells were
exposed to GANT61 (20 mM), hTERT mRNA levels were
significantly decreased within 24 hr and remained suppressed
through 72 hr (Fig. 3B). DU145 cells demonstrated decreased
GLI2 and hTERT mRNA levels when exposed to GANT61
(20 mM) while GLI1 transcript expression remained unaltered at
48 hr post-treatment (Fig. 3C). Upon exposure to GANT61
(20 mM), U87 cells demonstrated reductions in GLI1, GLI2 and
hTERT mRNA within 24 hr (Fig. 3D). These results confirmed
transcriptional regulation of hTERT expression by HH signaling
pathway in human cancer cells.
To dissect the mechanism of transcriptional regulation of
hTERT expression by HH signaling pathway, we monitored the
effects of HH signaling on hTERT promoter activity in HT29
cells. The full-length hTERT promoter-driven luciferase (FL
hTERT prom-luc) reporter and pRL-TK was transiently cotransfected into HT29-derived stable cell lines over-expressing
GLI1 or GLI2 or hTERT. Both GLI1 and GLI2DN expressing
cells demonstrated a 4-fold increase in hTERT promoter activity
within 24 hr of transfection (Fig. 4A). To identify the minimal
promoter length required for the HH-dependent effects on
hTERT promoter activity, the FL hTERT promoter (23337/
+438), and upstream deletion mutants (21226/+438 and 2233/
+438) -driven luciferase reporters were co-transfected into HT29
cells followed by exposure to either vehicle control or GANT61
(20 mM) for 24 hr. Data demonstrate that the 21226/+438 region
is the minimal requirement for HH-dependent hTERT promoter
activation although, the effects are less than that of the FL hTERT
promoter (Fig. 4B). The FL hTERT promoter activity was
significantly reduced upon blocking GLI activity with GANT61
(20 mM) (Fig. 4B). Next, we investigated whether the GLI
transcription factors directly interacted with the hTERT promoter

Cells were lysed in 1X CHAPS lysis buffer and 0.25 ug of the
lysates were used to perform TRAP assay. 1 mg of TS primer was
end-labeled with 3 ml of c P32ATP (Perkin Elmer) using 1 ml of
PNK (NEB) in a 20 ml reaction at 37uC for 45 min and purified
through a Sephadex G-25 column. In each reaction, 2 pmole of c32P end labeled TS primers, and reverse primers for PCR
amplification were mixed with 0.05 mM of dNTP, 20 mM TrisNCl
pH 8.3, 1.5 mM MgCl2, 63 mM KCl, 0.05% Tween 20, and
1 mM EGTA. 20 ng of RNase A was added with the cell lysate in
reactions treated with RNase. Telomerase-mediated primer
extension was carried out at 30uC for 30 min followed by PCR
amplification using the TS and reverse primers. Products from
TRAP assays were analyzed on 12.5% non-denaturing PAGE.
The TIFF files of the scanned gel images were quantified by
densitometry using the Image J software and the telomerase
activity was determined using the formula mentioned in the
manufacturer’s protocol for the TRAPEZE Telomerase detection
kit (Chemicon International Inc., MA).

Statistical Analysis
All the statistical analyses were performed using Prism
(GraphPad Software, La Jolla, CA).

Results
HH Signaling Upregulates hTERT Expression in Human
Cancer Cells
Dysregulated HH signaling is known to promote cell proliferation, cell cycle progression and cell survival in human cancer
cells, hence it was considered that the activated HH pathway may
also play a role in the replication potential of cancer cells.
Telomerase, a key regulator of the replication potential and closely
linked with cellular proliferation and survival, is therefore a strong
candidate for regulation by activated HH signaling in cancer cells.
To test this hypothesis, the relationship between the HH/GLI
signaling axis and telomerase expression was examined in multiple
human cancer cell lines. We abrogated the HH/GLI signaling axis
in multiple human cancer cell lines with pharmacological
PLOS ONE | www.plosone.org
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Figure 1. Pharmacologic inhibition of GLI1/GLI2 results in decreased hTERT protein expression in human cancer cells. A: HT29,
SW480 (colon carcinoma cells), C4-2, DU145 and PC3 (prostate cancer cells) were treated for 72 hr with either DMSO (vehicle control) or GANT61
(20 mM). B: U87 (GBM cells) were treated with GANT61 (20 mM) for 0–72 hr. Steady state levels of GLI1, GLI2 and hTERT protein were determined by
Western analysis. HSP90a/b was used as loading control.
doi:10.1371/journal.pone.0075253.g001

Figure 2. Genetic regulation of HH signaling modulates hTERT expression in human colon cancer cells. A: HT29, B: HCT116 cells were
transiently transfected with GLI3R (myc-tagged) for 48 hr or 72 hr, respectively. Steady state levels of GLI1, GLI2 and hTERT were determined by
Western analysis represented as densitometry of the blots in A with one representative hTERT blot (inset). Expression of GLI3R was determined using
anti-myc antibody. C: pBP empty vector (V) or full length GLI1 cDNA in pBP (GLI1) or GLI2DN in pBP (GLI2DN) was stably expressed into HT29 cells,
and cells were cultured for 10 passages. Steady state levels of GLI1, GLI2 and hTERT were measured by Western blot. HSP90a/b was used as a loading
control. *p,0.0001.
doi:10.1371/journal.pone.0075253.g002
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Figure 3. HH/GLI signaling regulates hTERT mRNA expression. A: HT29 cells stably expressing empty vector (V), GLI1 (GLI1) or GLI2DN
(GLI2DN) were analyzed for hTERT, GLI1 and GLI2 mRNA expression determined by Real-Time PCR. B: Exposure of HT29 cells to GANT61 (20 mM; 0–
72 hr) reduced expression of hTERT mRNA, determined by Real-Time PCR. C: DU145, D: U87 cells were exposed to GANT61 (20 mM; 48 hr or 24 hr
respectively) and GLI1, GLI2 and hTERT mRNA was measured by Real-time PCR. Data represent the mean 6 SD of 3 determinations. *p,0.05.
doi:10.1371/journal.pone.0075253.g003

hTERT mRNA level (Fig. 5B). Further, transient co-transfection
of the FL hTERT prom-luc reporter and either GLI1 or GLI2DN
expression plasmids did not increase the luciferase activity in 293T
cells (Fig. 5C). These findings underscore the context-dependent
functions of HH signaling pathway that selectively upregulates
hTERT expression in malignant cells in contrast to non-malignant
cells.

in cancer cells. In silico analysis of the hTERT promoter revealed 7
putative binding sites for the GLI family of transcription factors.
Both GLI1 and GLI2 antibodies precipitated fragments of the
hTERT promoter in ChIP analyses (Fig. 4C). PCR amplification
of the chromatin fragments using primers specific for hTERT
promoter regions resulted in amplicons that contained atleast the
core (2226/+360) hTERT promoter verified by sequencing the
PCR amplicons. Binding of GLI1 and GLI2 to the hTERT
promoter was reduced in the presence of GANT61 (20 mM) within
24 hr (Fig. 4D). BCL-2, previously reported as a target of both
GLI1 and GLI2, was used as positive control (Fig. 4C and 4D).

HH/GLI Signaling Regulates hTERT Enzymatic Activity in
Human Cancer Cells
Aberrant upregulation of hTERT expression is associated with
increased telomerase reverse transcriptase enzyme activity in
cancer cells. Hence, we tested the functional significance of the
HH/GLI/hTERT axis by measuring telomerase enzyme activity
in cancer cells. TRAP assay was used to determine the activity of
hTERT upon altering the HH/GLI signaling cascade. GANT61
(20 mM) administration led to reduced telomerase activity by
48 hr, which was sustained for up to 72 hr in HT29 cells (Fig. 6A,
quantified in Fig. S1). Conversely, stable derivatives of HT29 cells
expressing GLI2DN demonstrated increased telomerase activity in
comparison to the vector control, while GLI1 over-expressing cells
had a modest increase in telomerase activity (Fig. 6B, quantified in
Fig. S1). hTERT over-expressing cells with elevated telomerase
activity served as a positive control (Fig. 6B). Telomerase activity
was reduced in DU145 cells exposed to GANT61 (0–30 mM) for
48 hr (Fig. 6C). U87 cells also demonstrated reductions in
telomerase activity within 48 hr of exposure to GANT61
(20 mM), which was sustained till 72 hr (Fig. 6D). These
observations demonstrate that HH signaling upregulates both

HH/GLI Signaling does not Regulate hTERT Expression in
Non-malignant 293T Cells
We further investigated whether HH signaling transcriptionally
regulates hTERT in non-malignant cells. 293T cells are experimentally transformed but lack the ability to readily form tumors in
nude mice [20] and demonstrate an inducible HH/GLI signaling
axis [21]. We transiently transfected 293T cells with, either GLI1
or GLI2DN expression plasmids, and measured hTERT expression by western analysis. Although GLI1 and GLI2 protein
expressions were significantly elevated in the transfected 293T
cells, hTERT protein expression remained unaltered at 48 hr and
72 hr (Fig. 5A). hTERT over-expressing HT29 cells were used as
a positive control for hTERT protein analysis (Fig. 5A). We
measured hTERT transcript following transient transfection of
GLI2DN into 293T cells. Within 48 hr of transfection, 293T cells
demonstrated robust increase in GLI2 mRNA and .5 fold
increase in GLI1 mRNA levels, but no significant elevation in
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carcinoma [27,28], medulloblastoma [1,29], rhabdomyosarcoma
[30], glioma [1], pancreatic adenocarcinoma [31,32,33], prostate
cancer [34] and colon carcinoma [7,8,9,10]. In cancer cells,
autocrine ligand-dependent and oncogene-driven ligand-independent mechanisms maintain an active HH signaling cascade.
Aberrant HH activity drives tumor formation and tumor
maintenance by inducing pro-survival signals and blocking
apoptotic signals in cancer cells [9,35]. Another hallmark of
cancer is unlimited proliferation potential of cancer cells resulting
in immortality, however a link to dysregulated HH signaling was
not known.
Telomeres are specialized nucleoprotein structures at the
chromosomal ends that are important for chromosomal stability
and immortality of cells. Normal somatic cells encounter a gradual
attrition of telomere lengths with every DNA replication cycle
thereby limiting cellular lifespan. Normal stem cells and cancer
cells escape this check and replenish their telomere lengths by
increased telomerase activity. Telomerase is a ribonucleoprotein
comprised of human telomerase reverse transcriptase enzyme,
hTERT and telomerase RNA, hTR [36,37]. In cancer cells,
hTERT expression is aberrantly restored leading to increased
telomerase activity that maintains telomere length and confers
unlimited replication potential. hTERT expression and telomerase
activity has a close association [33] with human cancers [17,38].
Transformation of telomerase-negative normal cells in vitro
requires hTERT expression [39], delineating hTERT expression
as a rate-limiting step in telomere length homeostasis and cellular
transformation. The regulation of hTERT expression has been
extensively studied and numerous positive and negative regulators
have been identified [40,41].
In this study, we have shown for the first time that the HH
signaling pathway ensures limitless replication potential of cancer
cells by regulating hTERT expression and activity. In multiple
human cancer cell lines including colon, prostate and brain,
suppression of GLI1 and GLI2 expression using GANT61, a small
molecule inhibitor resulted in reduced expression of hTERT
mRNA, protein and enzyme activity. This finding indicated a
regulatory axis between HH signaling and hTERT in human
cancer cells. Using a genetic approach to suppress GLI1 and GLI2
using GLI3R, hTERT expression could also be inhibited in colon
cancer cells. Forced expression of GLI1 or a constitutively active
mutant of GLI2 expression increased hTERT mRNA and protein
in human colon cancer cells demonstrating HH/GLI-mediated
regulation of hTERT expression. hTERT promoter-driven
luciferase reporter activity was significantly reduced upon exposure to GANT61. Further, hTERT promoter activity was
significantly elevated in human colon cancer cells stably overexpressing GLI1 or GLI2. In silico analysis of the hTERT
promoter revealed 7 putative binding sites for the GLI family of
transcription factors suggesting a direct transcriptional mode of
regulation of hTERT by GLI. ChIP analysis demonstrated that
GLI1 and GLI2 proteins physically interacted with the hTERT
promoter and this interaction was sensitive to GANT61-mediated
inhibition of GLI1 and GLI2 activity. We have previously
reported that the GLI transcription factors are activated in a
SMO-independent manner via oncogenic pathways such as RAS/
RAF signaling axis in human colon cancer cells that are hence
more sensitive to inhibition of GLI instead of SMO [7,8]. Hence,
for the studies described here, the HH signaling axis was blocked
at the level of the GLI transcription factors using GANT61 (a
small molecule inhibitor of GLI1/2 activity) instead of SMO
inhibitors. Collectively, these findings demonstrated an HH/GLI/
hTERT axis in human cancer cells.

Figure 4. GLI1 and GLI2 proteins regulate hTERT promoter
activity. A: Stable derivatives of HT29 cells (described in Fig. 2C) were
co-transfected with a full-length hTERT promoter driven luciferase
(23337/+438) reporter and renilla luciferase (pRL-TK) constructs for
24 hr. Lysates were prepared, and luciferase activity determined as
described in Materials and Methods. hTERT promoter luciferase activity
was normalized against renilla luciferase activity and is presented as
mean 6 SD, n = 3. B: HT29 cells were co-transfected with either the full
length (23337/+438) or upstream deleted mutants (21226/+438 or
2233/+438) of hTERT prom-luc reporters and pRL-TK followed by
exposure to GANT61 (20 mM, 24 hr) and determination of luciferase
activity. hTERT promoter luciferase activity was normalized against
renilla luciferase activity and is presented as mean 6 SD, n = 3. C: HT29
cells were employed for ChIP analysis using antibodies specific for GLI1,
GLI2, or histone H3 (positive control, used for normalization). D: HT29
cells treated with GANT61 (20 mM, 24 hr) were similarly evaluated by
ChIP analysis. Subsequent Real-Time PCR used primers that flanked the
promoter regions of hTERT or the GLI target gene, BCL-2 (positive
control). *p,0.05.
doi:10.1371/journal.pone.0075253.g004

the hTERT expression and telomerase activity in human cancer
cells.

Discussion
HH signaling activity is essential for normal embryonic
development where it regulates cell differentiation and organ
formation in a gradient-dependent manner [22]. HH signaling
regulates cellular proliferation by transcriptionally modulating
genes that control cell cycle progression such as cyclin D, cyclin E
and, also by Ptch-mediated sequestration of cyclin B in the
cyctoplasm [23,24,25]. In the adult stage, active HH signaling
persists in a small subset of cells that confer regenerative potential
for the mature organs [26]. Dysregulation of HH signaling has
been reported in multiple human cancers, including basal cell

PLOS ONE | www.plosone.org
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Figure 5. Over-expression of GLI1 or GLI2 in non-malignant 293T cells does not influence hTERT expression. A: 293T cells were
untreated (UT), transiently transfected with empty vector (V) or GFP-tagged GLI1 (GLI1) or GFP-tagged GLI2DN (GLI2DN). Expression of GLI1, GLI2 and
hTERT was determined for 48 and 72 hrs by Western analysis. HSP90a/b was used as loading control and GFP was used to mark exogenously
expressed GFP-tagged GLI proteins. Total cell lysate from HT29 cells stably expressing hTERT (HT29+hTERT) served as positive control. B: 293T cells
transiently transfected with vector or GLI2 (as described in Figure 5A) were analyzed for GLI1, GLI2 and hTERT mRNA expression via qPCR. Data
represent the mean 6 SD of 3 determinations. C: 293T cells transiently co-transfected with FL-hTERT prom-luc, renilla luceferase reporters and vector,
GLI1 or GLI2 (as described in Figure 5A). 24 hr post-transfection the cells were analyzed for luciferase activity. hTERT promoter-driven luciferase
activity was normalized against renilla luciferase activity and is represented as mean 6 SD, n = 3. *p,0.05.
doi:10.1371/journal.pone.0075253.g005

Recent reports identified a direct link between the Wnt/bcatenin signaling pathway and hTERT expression in normal
embryonic and adult stem cells and cancer cells [42,43,44].
Interestingly, our data demonstrate that there is a contextdependent regulation of the hTERT promoter by the HH/GLI
signaling pathway. The HH/GLI signaling axis increased hTERT
expression in the panel of colon, prostate and brain cancer cells
investigated here, in contrast to non-malignant 293T cells, where
hTERT expression was unresponsive to HH/GLI activity. This
underscores the differential regulation of genes in normal versus
noeplastic cells. Recent evidences suggest that the hTERT
promoter is regulated by epigenetic modification. For example,
SYMD3, a histone methyltransferase upregulated and implicated
in oncogenesis, directly binds the hTERT promoter and serves as
a licensing factor for hTERT transcription by enabling the
interaction of other transcription factors [45]. Such epigenetic
regulators may determine context-dependent regulation of
hTERT expression and activity by various transcription factors.
It remains to be determined whether HH/GLI signaling activity at
the hTERT promoter is dependent on such epigenetic regulators.
However, context-dependent functional heterogeneity is a wellknown characteristic of the HH signaling pathway [3]. By virtue of
PLOS ONE | www.plosone.org

harboring activator and repressor functions, the GLI proteins can
elicit a context-dependent positive or negative impact on cellular
functions. GLI1 lacks the amino-terminal repressor domain and
serves as an activator [46]. GLI2, which has an amino-terminal
repressor domain and a carboxy-terminal activator domain,
functions as a repressor in its full-length form and upon truncation
of its amino-terminus converts to a transcriptional activator in
cells. GLI3 also possesses amino- and carboxy- termini but
functions predominantly as a transcriptional repressor [47]. The
three GLI proteins co-operate in HH-responsive cells to integrate
the HH signals in conjunction with other cellular signals. The net
result of the collective activator and repressor functions of GLI1,
GLI2 and GLI3 dictate the status of the GLI transcription
program which modulate specific HH target genes in cells [48].
HH/GLI signaling can function in a species-dependent manner,
eg. GLI1 mediates SHH-induced differentiation of frog neural
plate, which is blocked by GLI2 and GLI3 activity [49]. Positive or
negative activity of the GLI proteins is developmental stage- and
target-dependent [49]. In mice, GLI2 and GLI3 transcription
factors have essential and partially overlapping functions while
GLI1 is dispensable [50]. Such observations emphasize the
context-dependent roles of the HH/GLI axis in regulating target
7
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Figure 6. The HH/GLI signaling pathway regulates telomerase activity. A: HT29 cells were treated with GANT61 (20 mM) for 0–72 hr, and
lysates were extracted at intervals for TRAP analysis. 100 bp DNA ladder was used as a molecular marker (M). B: HT29 cells stably expressing vector
(V), GLI1 or GLI2 (GLI2DN) (described in Figure 3A) were evaluated for telomerase activity by TRAP assay. hTERT over-expressing cells were used as
positive control. C: U87 and D: DU145 cells were treated with GANT61 (0–30 mM; 0–72 hr) and telomerase activity was analyzed by the TRAP assay.
doi:10.1371/journal.pone.0075253.g006

genes. Binding partners such as Zic proteins also regulate the
functions of the GLI transcription factors in a context-dependent
manner [51]. GLI transcriptional activity is also regulated by the
acetylation status of GLI proteins [52].
In summary, our results demonstrate that HH signaling
regulates hTERT, which determines the replication potential of
cancer cells. Suppression of both GLI1 and GLI2 functions
reduced hTERT mRNA and protein expression in human colon,
PLOS ONE | www.plosone.org

prostate and brain cancer cell lines. Exogenous expression of GLI1
or GLI2 increased hTERT mRNA and protein expressions and
hTERT promoter-luciferase activity in human colon cancer cells.
Blocking GLI transcriptional function reduced the GLI proteinhTERT promoter interaction. Exogenous expression of GLI1 or
GLI2DN in the non-malignant 293T cells failed to alter the levels
of hTERT mRNA and protein, or hTERT promoter-luciferase
activity. Blocking GLI transcriptional activity reduced the
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telomerase activity in human colon, prostate and GBM cells, while
stable over-expression of GLI2 in HT29 cells increased telomerase
activity. Collectively, our data reveal a previously unknown
function of the HH/GLI axis in controlling unlimited replication
potential of cancer cells by transcriptionally regulating hTERT
gene expression, a critical determinant of the life span of cancer
cells.

densitometrically in HT29 cells treated with GANT61 (20 mM) for
0–72 hr (A) and HT29 cells stably expressing vector (V), GLI1 or
GLI2 (GLI2DN) (B) as described in Materials and Methods. Data
is represented as mean 6 SD, n = 3. *p,0.05.
(TIF)
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